View Full List
Galapagos Genomics Ord
Streaming Delayed Price
Updated: 11:35 AM EST, Feb 29, 2024
Add to My Watchlist
All News about Galapagos Genomics Ord
Galapagos' Filgotinib Shows Clinical Benefit In Ulcerative Colitis Non-Responding Patients
October 05, 2021
Galapagos NV (NASDAQ: GLPG) announced results of two post-hoc analyses from the SELECTION and SELECTION LTE studies of filgotinib for active ulcerative colitis (UC...
Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's Disease
October 04, 2021
Galapagos NV (NASDAQ: GLPG) has randomized the last patient into the DIVERSITY Phase 3 study of filgotinib in the induction and maintenance of remission in...
Galapagos' Long-Serving CEO Onno Van De Stolpe To Exit After R&D Setbacks
August 31, 2021
After 22 years at the helm of Galapagos NV (NASDAQ: GLPG), chief executive Onno van de Stolpe has decided it is time to retire and hand the reins to new...
Galapagos' Another Psoriasis Candidate Shows Efficacy, Safety Profile In Mid-Stage Study
July 15, 2021
Galapagos NV (NASDAQ: GLPG) reported topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients. At Week 4, four...
Galapagos Shares Drop As SIK Inhibitor Fails To Show Positive Outcomes In Ulcerative Colitis, Rheumatoid Arthritis Patients
July 15, 2021
Galapagos NV (NASDAQ: GLPG) reports topline results from three studies evaluating GLPG3970, a SIK inhibitor, in psoriasis, ulcerative colitis (UC), and rheumatoid...
Galapagos Drops Early Metabolic & Osteoarthritis Programs, Reorganizes R&D Efforts
May 07, 2021
Galapagos NV (NASDAQ: GLPG) is chopping its pipeline to conserve cash while its business development team pursues a mission to find a “transformative...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Terms and Conditions